Causaly is an AI platform that uses natural language processing (NLP) and machine learning techniques to analyze vast amounts of scientific literature, extracting relevant information and identifying the causal relationships between biological concepts. By understanding the connections between genes, proteins, diseases, and drugs, Causaly helps researchers make informed decisions in their pursuit of new treatments and therapies. Currently, the drug discovery AI startup counts 12 of the top 20 pharmaceutical companies among its customers.
Causaly has raised $60 million in a Series B round. The new round was led by ICONIQ Growth and previous backers Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures, and Visionaries Club. In total, Causaly has raised $93 million till that moment.
Causaly, London, England, United Kingdom, was founded in 2018 by Yiannis Kiachopoulos and Artur Saudabayev. “Recent advances in AI open completely new possibilities, and there is a great need to develop transparent AI systems that science leaders can trust,” said Yiannis Kiachopoulos, cofounder and CEO of Causaly, in a statement provided to VentureBeat. “Knowledge is the lifeblood of research organizations, and we remain committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.”
